Spect    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病41

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
41 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04193527
(ClinicalTrials.gov)
July 20202/12/2019A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese PatientsA Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy ControlsParkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP)Drug: DaTSCAN™ Ioflupane (123I) InjectionGE HealthcarePPDNot yet recruiting40 Years80 YearsAll172Phase 3China
2NCT04265209
(ClinicalTrials.gov)
May 20206/2/2020[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential TremorNon-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.Parkinson Disease;Essential TremorDrug: SPECT;Drug: PETZionexaNULLNot yet recruiting35 Years80 YearsAll112Phase 3NULL
3NCT02967250
(ClinicalTrials.gov)
April 1, 202013/9/2016Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA TreatmentParkinson DiseaseDrug: ursodeoxycholic acidUniversity of MinnesotaNULLNot yet recruiting18 YearsN/AAll20Phase 1United States
4NCT03815916
(ClinicalTrials.gov)
December 19, 201918/1/201931P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's DiseaseA Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's DiseaseParkinson's DiseaseDrug: Gold NanocrystalsClene NanomedicineUniversity of Texas Southwestern Medical CenterRecruiting30 Years80 YearsAll30Phase 2United States
5EUCTR2019-000247-27-FR
(EUCTR)
02/05/201905/03/2019Study to demonstrate an at least equivalent performance of a new test in brain imaging test compared to the reference examination to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. - DATTEP Patients suffering from an essential tremor or with Parkinson's disease.
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Classification code 10015496;Term: Essential tremor;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Trade Name: DaTSCAN 74 MBq/ml solution for injection
Product Code: [18F] LBT-999
ZIONEXANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
112Phase 3France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03531086
(ClinicalTrials.gov)
January 19, 20188/5/2018Idiopathic Parkinson's Progression and Dopamine Transporter SPECTExploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's DiseaseParkinson DiseaseDrug: Ioflupane I 123Julie GurwellNULLActive, not recruiting40 Years75 YearsAll12United States
7NCT03973502
(ClinicalTrials.gov)
June 12, 201730/5/2019Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PDApplication of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) in Research of the Association Between HCV Infection and Parkinson's Disease.Hepatitis C;Hepatitis B;Parkinson DiseaseDrug: 18F-DOPA PETNational Taiwan University HospitalNULLRecruiting20 YearsN/AAll230N/ATaiwan
8JPRN-jRCTs051180098
09/06/201606/03/2019The DAT-SPECT study for the benefit of Selegilline or Zonisamide in Parkinson's DiseaseA comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease Parkinson's disease;034034L-Dopa/DCI only : The drug is administered per oral at 300 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + selegiline : L-Dopa/DCI is administered per oral at 300 mg/day and selegiline is administered at 5 mg/day. The treatment is started within 14 days after registration and continued until day 365.
L-Dopa/DCI + zonisamide : L-Dopa/DCI is administered per oral at 300 mg/day and zonisamide is administered at 25 mg/day. The treatment is started within 14 days after registration and continued until day 365.
Ito HidefumiNULLRecruiting>= 55age old< 80age oldBoth120Phase 2Japan
9EUCTR2015-004238-85-ES
(EUCTR)
27/01/201610/12/2015Brain SPECT in premotor stage of Parkinson diseaseIctal brain SPECT in the premotor stage of Parkinson disease Parkinson disease
MedDRA version: 18.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: CERETEC (TM) Estabilizado
Product Name: Ceretec
INN or Proposed INN: Ceretec
Other descriptive name: TECHNETIUM (99MTC) EXAMETAZIME
IDIBAPSNULLNot RecruitingFemale: yes
Male: yes
30Phase 2Spain
10NCT02438215
(ClinicalTrials.gov)
August 20147/8/2014Study of IRX4204 for Treatment of Early Parkinson's DiseaseAn Open-Label, Single Site Study Using [123I]ß-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease SubjectsParkinson's DiseaseDrug: IRX4204Io TherapeuticsNULLCompleted18 YearsN/ABoth15Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01931488
(ClinicalTrials.gov)
August 201314/8/2013124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.Parkinson Disease;Neuroendocrine TumorsOther: MIBG label with I123 or I124;Device: SPECT imagingTel-Aviv Sourasky Medical CenterNULLRecruiting18 YearsN/ABoth40Phase 2Israel
12NCT01264861
(ClinicalTrials.gov)
March 201120/12/2010A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain ImagingOpen-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease PatientsParkinson DiseaseDrug: SafinamideNewronNULLTerminated40 Years80 YearsAll5Phase 2United States
13NCT00970229
(ClinicalTrials.gov)
July 200931/8/2009Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy ControlsParkinson Disease;Huntington DiseaseDrug: [123I]MNI-420Institute for Neurodegenerative DisordersNULLCompleted18 YearsN/AAll19Phase 1United States
14NCT00870974
(ClinicalTrials.gov)
March 200926/3/2009A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsEvaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric ConditionsParkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive ImpairmentDrug: [18F]FPEBInstitute for Neurodegenerative DisordersNULLCompleted18 Years85 YearsAll48Phase 1United States
15NCT00612872
(ClinicalTrials.gov)
January 200816/1/2008Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy SubjectsEvaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy SubjectsParkinson Disease;Alzheimer Disease;Healthy Controls;Multiple SclerosisDrug: [123I]CLINDEInstitute for Neurodegenerative DisordersNULLTerminated30 Years50 YearsAll46Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00566462
(ClinicalTrials.gov)
October 200729/11/2007Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECTAssessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECTParkinson's DiseaseDrug: perampanel;Drug: placeboEisai Inc.NULLTerminated30 YearsN/AAll1Phase 2United States
17NCT00556764
(ClinicalTrials.gov)
July 20078/11/2007Development of Cognitive Assessment Tools in Parkinson DiseaseDevelopment of Cognitive Assessment Tools in Parkinson DiseaseParkinson DiseaseDrug: [123I] IBVM and SPECT imaging;Drug: Subjects will undergo the 123-I IBVM imaging visitInstitute for Neurodegenerative DisordersDepartment of Defense;University of OklahomaCompleted30 YearsN/ABoth75Phase 0United States
18NCT00480701
(ClinicalTrials.gov)
February 200730/5/2007Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer DiseaseEvaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer DiseaseAlzheimer Disease;Parkinson DiseaseDrug: [123I]-IBVMInstitute for Neurodegenerative DisordersNULLCompleted50 YearsN/ABoth26Phase 2United States
19NCT00427674
(ClinicalTrials.gov)
January 200725/1/2007Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease PatientsPhase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human SubjectsParkinson DiseaseDrug: [123I] mZINT injection and serial dynamic SPECT imagingInstitute for Neurodegenerative DisordersMolecular NeuroImagingTerminated18 Years70 YearsBoth28Phase 1United States
20NCT00397228
(ClinicalTrials.gov)
November 20066/11/2006ALTROPANE® SPECT Imaging in Patients With Parkinson DiseaseOptimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson DiseaseParkinson DiseaseDrug: ALTROPANE®Molecular NeuroImagingInstitute for Neurodegenerative DisordersCompleted30 YearsN/ABoth27Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT00397696
(ClinicalTrials.gov)
November 20067/11/2006Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons DiseaseEvaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease SubjectsParkinson DiseaseDrug: [123I] 5-IAInstitute for Neurodegenerative DisordersDepartment of DefenseCompleted21 YearsN/ABoth9Phase 2United States
22NCT00404170
(ClinicalTrials.gov)
November 200622/11/2006Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson DiseaseAssessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT CohortParkinson DiseaseDrug: B-CIT and SPECT imagingInstitute for Neurodegenerative DisordersUnited States Department of DefenseCompleted30 YearsN/AAll396Phase 2United States
23NCT00387075
(ClinicalTrials.gov)
November 200610/10/2006A Study Evaluating Potential Screening Tools for Detecting Parkinson DiseaseParkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson DiseaseParkinson DiseaseProcedure: [123I]ß-CIT and SPECT imaging;Drug: [123I]ß-CITInstitute for Neurodegenerative DisordersUnited States Department of Defense;Molecular NeuroImagingActive, not recruiting50 YearsN/AAll3000Phase 2United States
24EUCTR2005-004949-34-SE
(EUCTR)
06/09/200627/03/2006A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start StudyA randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Boehringer Ingelheim ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
500Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden
25EUCTR2005-004949-34-DE
(EUCTR)
04/08/200630/03/2006A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start StudyA randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: SIFROL
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Boehringer Ingelheim Pharma GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
500Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26EUCTR2005-004949-34-GB
(EUCTR)
19/06/200624/03/2006 A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease The main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536
Boehringer Ingelheim LtdNULLNot Recruiting Female: yes
Male: yes
500Phase 4Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
27EUCTR2005-004949-34-ES
(EUCTR)
29/05/200621/04/2006A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease. Protocol includes DAT SPECT of a sub-set of patients Estudio aleatorizado, doble ciego, controlado con placebo, para examinar la eficacia y seguridad del tratamiento temprano frente al tratamiento retrasado con pramipexol en pacientes con inicio de Parkinson - Pramipexole Early Start StudyA randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease. Protocol includes DAT SPECT of a sub-set of patients Estudio aleatorizado, doble ciego, controlado con placebo, para examinar la eficacia y seguridad del tratamiento temprano frente al tratamiento retrasado con pramipexol en pacientes con inicio de Parkinson - Pramipexole Early Start Study Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536
Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol, Mirapexin
Product Name: Sifrol, Mirapexin
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Boehringer Ingelheim España, S.A.NULLNot RecruitingFemale: yes
Male: yes
500Finland;Spain;Austria;Germany;Italy;United Kingdom;Sweden
28EUCTR2005-004949-34-FI
(EUCTR)
17/05/200621/04/2006A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start StudyA randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Trade Name: Sifrol
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Boehringer IngelheimBoehringer Ingelheim Finland KyAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
500Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden
29EUCTR2005-004949-34-AT
(EUCTR)
18/04/200621/03/2006A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start StudyA randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s diseaseThe main protocol includes DAT SPECT brain imaging of a sub-set of patients - Pramipexole Early Start Study Parkinson's disease
MedDRA version: 6.1;Level: pref;Classification code 10061536
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Product Name: Sifrol
Product Code: SND 919 CL2 Y
INN or Proposed INN: Pramipexole
Boehringer Ingelheim Austria GmbHNULLNot RecruitingFemale: yes
Male: yes
500Finland;Germany;United Kingdom;Spain;Italy;Austria;Sweden
30EUCTR2004-001485-41-GB
(EUCTR)
26/07/200521/06/2005A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/AA single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).Trade Name: Sinemet
Product Name: Sinemet
INN or Proposed INN: carbidopa/levodopa
Trade Name: Cabaser
Product Name: Cabaseril
INN or Proposed INN: Cabergoline
Trade Name: DaTSCAN
Product Name: DatSCAN
INN or Proposed INN: Ioflupane [123 I]
Institute for Neurodegenerative DisordersNULLNot RecruitingFemale: yes
Male: yes
120United Kingdom;Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2004-001485-41-ES
(EUCTR)
28/04/200530/01/2006A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s DiseaseA single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).Trade Name: SINEMET
Product Name: carbodopa/levadopa
INN or Proposed INN: CARBODOPA LEVADOPA
Trade Name: SOLIGEN
Product Name: Cabergoline
INN or Proposed INN: CABERGOLINA
Trade Name: DaTSCAN
INN or Proposed INN: Ioflupane [123I]
Institute for Neurodegenerative DisordersNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120United Kingdom;Spain
32EUCTR2004-001485-41-AT
(EUCTR)
20/04/200516/03/2005A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/AA single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease - N/A Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).Trade Name: Sinemet
Product Name: Sinemet
INN or Proposed INN: carbidopa/levodopa
Trade Name: Cabaseril
Product Name: Cabaseril
INN or Proposed INN: Cabergoline
Trade Name: DaTSCAN
Product Name: DatSCAN
INN or Proposed INN: Ioflupane [123 I]
Institute for Neurodegenerative DisordersNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Spain;Austria;United Kingdom
33NCT00129181
(ClinicalTrials.gov)
January 20059/8/2005Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's DiseaseA Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's DiseaseParkinson Disease;Parkinsonian SyndromeDrug: cabergoline;Drug: carbidopa/levodopa;Procedure: DATscan and SPECT imagingInstitute for Neurodegenerative DisordersPfizer;GE HealthcareCompleted40 YearsN/ABoth30N/AAustria;Germany;Italy;Spain;United Kingdom
34NCT00200447
(ClinicalTrials.gov)
March 200412/9/2005An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)Parkinson's DiseaseDrug: carbidopa/l-dopa;Drug: carbidopa/l-dopa/entacapone;Drug: Stalevo;Procedure: [123I]-IBZM imagingMolecular NeuroImagingNULLCompleted30 YearsN/ABoth3Phase 2NULL
35NCT00096720
(ClinicalTrials.gov)
February 200412/11/2004Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's DiseaseInvestigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson'sParkinson Disease;Parkinsonian SyndromeDrug: levodopa;Drug: Mirapex (pramipexole);Procedure: [123I]ß-CIT and SPECT imagingInstitute for Neurodegenerative DisordersBoehringer Ingelheim;Department of DefenseCompleted30 YearsN/ABoth112Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT00058721
(ClinicalTrials.gov)
April 200311/4/2003Single Photon Emission Computed Tomography to Study Receptors in Parkinson's DiseaseSPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's DiseaseParkinson DiseaseDrug: I-123-5-IA85380National Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth60N/AUnited States
37NCT00129675
(ClinicalTrials.gov)
February 200311/8/2005Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic UncertaintyDevelopment of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's SymptomsParkinsonian SyndromeDrug: [123I]ß CITInstitute for Neurodegenerative DisordersMolecular NeuroImagingCompleted21 YearsN/ABoth169Phase 2United States
38NCT00209508
(ClinicalTrials.gov)
November 200213/9/20052 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PDRandomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.Parkinson's DiseaseDrug: GPI 1485Eisai Inc.Symphony Neuro Development CompanyCompleted40 Years80 YearsBoth200Phase 2NULL
39NCT00117819
(ClinicalTrials.gov)
March 200130/6/2005A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's DiseaseDynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian SyndromeParkinsonian SyndromeDrug: [123I]ß CIT and SPECT imagingInstitute for Neurodegenerative DisordersIndiana University;Albany Medical CollegeCompleted22 YearsN/ABoth232Phase 2United States
40NCT00134784
(ClinicalTrials.gov)
April 200023/8/2005Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's DiseaseParkinson DiseaseDrug: [123I]B-CIT SPECT imagingInstitute for Neurodegenerative DisordersUnited States Department of DefenseCompleted22 YearsN/AAll142Phase 2NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT00132626
(ClinicalTrials.gov)
September 199218/8/2005Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian SyndromeDynamic SPECT Imaging With [123I]ß-CIT in Patients With ParkinsonismParkinson's Disease;Parkinsonian SyndromeDrug: [123I]ß-CIT and SPECT imagingInstitute for Neurodegenerative DisordersMolecular NeuroImaging;National Institutes of Health (NIH)Completed35 YearsN/AAll500Phase 2NULL